Chiglitazar is a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist, which passed phase III clinical trials and was newly approved in China for use as an adjunct to diet and exercise in glycemic control in adult patients with Type 2 Diabetes (T2D). To explore the circulating protein...
In this project, we used biotin-labeled compound 1 to pull down proteins in U2OS cell lysates with or without the competition of free compound 1, and then to identify the cellular binding of compound 1.
